HRAS G13X
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene HRAS
Variant G13X
Impact List missense
Protein Effect unknown
Gene Variant Descriptions HRAS G13X indicates any HRAS missense mutation that results in replacement of the glycine (G) at amino acid 13 by a different amino acid. HRAS G13 mutations are hotspot mutations that often result in decreased Hras GTPase activity, leading to activation of downstream signaling and transformation of cultured cells (PMID: 8430333, PMID: 21850009, PMID: 24224811, PMID: 26985062).
Associated Drug Resistance
Category Variants Paths

HRAS mutant HRAS G13X

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_005343.4
gDNA chr11:g.534284_534286
cDNA c.37_39
Protein p.G13
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_005343.3 chr11:g.534284_534286 c.37_39 p.G13 RefSeq GRCh38/hg38
NM_005343.4 chr11:g.534284_534286 c.37_39 p.G13 RefSeq GRCh38/hg38
NM_001130442.2 chr11:g.534284_534286 c.37_39 p.G13 RefSeq GRCh38/hg38
NM_176795.4 chr11:g.534284_534286 c.37_39 p.G13 RefSeq GRCh38/hg38
NM_001130442.3 chr11:g.534284_534286 c.37_39 p.G13 RefSeq GRCh38/hg38
NM_005343 chr11:g.534284_534286 c.37_39 p.G13 RefSeq GRCh38/hg38
NM_001130442 chr11:g.534284_534286 c.37_39 p.G13 RefSeq GRCh38/hg38
NM_176795.5 chr11:g.534284_534286 c.37_39 p.G13 RefSeq GRCh38/hg38
NM_176795 chr11:g.534284_534286 c.37_39 p.G13 RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT06881784 Phase III Docetaxel Daraxonrasib Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) (RASolve 301) Recruiting USA | POL | NLD | ITA | IRL | FRA | ESP | DEU | CHE | BEL 5
NCT05379985 Phase I Daraxonrasib Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS Recruiting USA 0
NCT06625320 Phase III Fluorouracil + Leucovorin + Liposomal irinotecan Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Gemcitabine + Nab-paclitaxel Daraxonrasib Phase 3 Study of RMC-6236 in Patients with Previously Treated Metastatic Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 302) Recruiting USA | ITA | FRA | ESP | DEU 2